Sort
51,593 grants matching “hepatitis”
Gulf Longitudinal Follow-up (GuLF) Study
$1,185,318Dale P Sandler · National Institute Of Environmental Health Sciences · ZIA · FY2022 · ES
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism
$1,185,291Steffanie A Strathdee · University Of California, San Diego · R01 · FY2020 · DA
Technology-Dev-Core
$1,184,948Sally M McFall · Northwestern University · U54 · FY2022 · EB
Cornell Clinical Trials Unit
$1,184,443Roy M Gulick · Weill Medical Coll Of Cornell Univ · U01 · FY2008 · AI
UCSF Liver Core Center
$1,184,375Jacquelyn J. Maher · University Of California, San Francisco · P30 · FY2014 · DK
DEMYELINATION DISEASE--VIRAL AND IMMUNE FUNCTION
$1,183,258University Of Southern California · P01 · FY2001 · NS
Project SHIELD: Police Education to Support Public Health in Kentucky
$1,182,981Javier Cepeda · Johns Hopkins University · R33 · FY2025 · DA
Mayo Translational PKD Center (MTPC)
$1,182,744Vicente E Torres · Mayo Clinic Rochester · P30 · FY2011 · DK
ADULT AIDS CLINICAL TRIALS UNIT
$1,182,738Henry H. Balfour · University Of Minnesota · U01 · FY2007 · AI
SILVIO O.CONTE DIGESTIVE DISEASES RESEARCH CORE CENTERS
$1,182,687James Lorenzen Boyer · Yale University · P30 · FY2006 · DK
Molecular Mechanisms of TGF-beta Signaling Pathway
$1,182,286Ying Zhang · Basic Sciences · Z01 · FY2007 · CA
PCOS and androgen-related disease modeling and drug testing in Multi-organ Integrated Microfluidic Reproductive Platform
$1,181,686Ji-Yong Julie Kim · Northwestern University At Chicago · UH3 · FY2021 · ES
PCOS and androgen-related disease modeling and drug testing in Multi-organ Integrated Microfluidic Reproductive Platform
$1,181,686Ji-Yong Julie Kim · Northwestern University At Chicago · UH3 · FY2020 · ES
The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)
$1,181,637Charles W. Flexner · Johns Hopkins University · R24 · FY2025 · AI
Conduct Synthesis and Acquire Batches of Compounds for Subsequent Biological In Vitro and In Vivo Testing
$1,181,599Mark Middleton · Starks Associates, Inc. · N01 · FY2022 · AI
PCOS and androgen-related disease modeling and drug testing in Multi-organ Integrated Microfluidic Reproductive Platform
$1,181,132Teresa K Woodruff · Northwestern University At Chicago · UG3 · FY2017 · ES
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis
$1,180,713Serena Patricia Koenig · Brigham And Women'S Hospital · U01 · FY2023 · AI
The National Drug Abuse Treatment Clinical Trials Network
$1,180,255Walter Nmn Ling · University Of California Los Angeles · U10 · FY2011 · DA
Synthesis of Therapeutic Agents for Treatment of Infectious Diseases
$1,179,826David Starks · Starks Associates, Inc. · N01 · FY2014 · AI
TIM recognition of phosphatidylserine regulates innate and adaptive immunity
$1,179,735Gordon James Freeman · Dana-Farber Cancer Inst · P01 · FY2014 · AI
Center for CAM Research on Autoimmune and Inflammatory Diseases
$1,179,735Prakash S. Nagarkatti · University Of South Carolina At Columbia · P01 · FY2011 · AT
Liver Pathobiology and Gene Therapy Research Core Center
$1,179,692David A Shafritz · Albert Einstein College Of Medicine · P30 · FY2007 · DK
Liver Pathobiology and Gene Therapy Research Core Center
$1,179,692David A Shafritz · Albert Einstein College Of Medicine · P30 · FY2008 · DK
Task A10 Efficacy Testing of Therapeutics Against HCV in a Mouse Model
$1,178,604 · N01 · FY2010 · AI
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism
$1,178,536Steffanie A Strathdee · University Of California, San Diego · R01 · FY2024 · DA